(Q38895152)

7 September 2017

title

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer (English)

1 reference

7 September 2017

main subject

ascending cholangitis

0 references

1 reference

12

Masatoshi Kudo

1 reference

7 September 2017

Hisato Kawakami

1

1 reference

7 September 2017

Junko Tanizaki

2

1 reference

7 September 2017

Kaoru Tanaka

3

1 reference

7 September 2017

Koji Haratani

4

1 reference

7 September 2017

Hidetoshi Hayashi

5

1 reference

7 September 2017

Masayuki Takeda

6

1 reference

7 September 2017

Ken Kamata

7

1 reference

7 September 2017

Mamoru Takenaka

8

1 reference

7 September 2017

Masatomo Kimura

9

1 reference

7 September 2017

Takaaki Chikugo

10

1 reference

7 September 2017

Takao Sato

11

1 reference

7 September 2017

Akihiko Ito

13

1 reference

7 September 2017

Kazuhiko Nakagawa

14

1 reference

7 September 2017

language of work or name

1 reference

20 March 2017

1 reference

Investigational New Drugs

7 September 2017

published in

1 reference

7 September 2017

volume

35

1 reference

7 September 2017

issue

4

1 reference

7 September 2017

page(s)

529-536

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

A review of the physiological and immunological functions of biliary epithelial cells: targets for primary biliary cirrhosis, primary sclerosing cholangitis and drug-induced ductopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

The immunobiology of bile and biliary epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0453-0

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-017-0453-0

1 reference

Dimensions Publication ID

7 September 2017

1084504012

0 references

1 reference